2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

904. Outcomes Research: Hemoglobinopathies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Treatment Considerations, Drug Development, Biological Therapies, Transfusion, Transplantation, Women’s Health, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, MDS, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Pediatric, Pregnant
PAPER

2666 The impact of normal saline bolus on pain control in patients with sickle cell disease hospitalized with acute pain

Corrie E. Chumpitazi, MD, MC, Dunia Hatabah, MD2, Noor Alzraikat, MD3, Rawan Korman, MD4, Fahd Ahmad, MD5, Gladstone Airewele, MD6, Samina Ali, MD7, Bolanle Akinsola, MD8, Nitya Bakshi, MBBS, MS9, David C. Brousseau, MD10, Kathleen Brown, MD11, Andrew Campbell, MD12, T. Charles Casper, PhD13, Todd P Chang, MD14, Daniel Cohen, MD15, Keli D. Coleman, MD16, Laura Covelo, NP-C17, Andrea T. Cruz, MD, MPH18, Lauren Cutler19, Christopher Denton, MD20, Amy L Drendel, DO MS21, Angela Ellison, MD22, Melanie Fields, MD, MSCI23, Hailey Jensen24, Sara Leibovich, MD25, Derek Meyer26, Seth Otto27, Jonathan Race, PhD28, Chris A. Rees, MD, MPH29, Allison Remiker, MD30, Nidhi V. Singh, MD31, Alexis A. Thompson, MD MPH32, Daniel Tsze, MD MPH33, Elliott P. Vichinsky, MD34, Anthony Villella, MD35, Hagar Wilkinson, PharmD36, Bridget Wynn, MD37, Carlton Dampier, MD38, Claudia Morris, MD39
1 Duke University, Durham, North Carolina, United States
2 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
3 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
4 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
5 Washington University, Saint Louis, Missouri, United States
6 Baylor College of Medicine, Houston, North Carolina, United States
7 University of Alberta, Edmonton, Alberta, Canada
8 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
9 Yale University, New Haven, Connecticut, United States
10 Nemours Children's Hospital, Wilmington, Delaware, United States
11 Children's National Medical Center, Washington DC, District of Columbia, United States
12 Children's National Medical Center, Washington DC, District of Columbia, United States
13 University of Utah, Salt Lake City, Utah, United States
14 Children's Hospital of Los Angeles, Los Angeles, California, United States
15 Nationwide Children's Hospital, Columbus, Ohio, United States
16 Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
17 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
18 Baylor College of Medicine, Houston, North Carolina, United States
19 University of Utah, Salt Lake City, Utah, United States
20 Children's Hospital of Los Angeles, Los Angeles, California, United States
21 Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
22 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
23 Washington University in St. Louis, St. Louis, Missouri, United States
24 University of Utah, Salt Lake City, Utah, United States
25 University of California San Francisco, San Francisco, California, United States
26 University of Utah, Salt Lake City, Utah, United States
27 University of Utah, Salt Lake City, Utah, United States
28 University of Utah, Salt Lake City, Utah, United States
29 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
30 Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States
31 Baylor College of Medicine, Houston, North Carolina, United States
32 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
33 Columbia University, New York, New York, United States
34 University of California San Francisco, San Francisco, California, United States
35 Nationwide Children's Hospital, Columbus, Ohio, United States
36 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
37 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States
38 Children's Healthcare of Atlanta, Atlanta, United States
39 Children's Healthcare of Atlanta Office Park, Brookhaven, Georgia, United States

Introduction: Nearly 80% of all emergency department (ED) visits and the majority of admissions for patients with sickle cell disease (SCD) are due to vaso-occlusive pain events (VOE). Administration of an intravenous fluid bolus (FB), defined as ≥10ml/kg of fluid administered over 60 minutes or less, is frequently used in the acute management of children with SCD-VOE, yet there is little to no evidence of benefit and some evidence of harm. Several retrospective cohort studies have shown FB administration, particularly normal saline bolus (NSB), is associated with increased risk of acute chest syndrome (ACS) and worsened SCD-VOE. Despite 2014 National Heart, Lung and Blood Institute (NHLBI) guidelines recommending against use of intravenous FB in normovolemic patients with SCD-VOE, a previous study found 65% of children seen across 20 pediatric EDs received a NSB, and this practice was associated with worse ED pain and increased hospital admission. We sought to evaluate the pain outcomes associated with NSB in children presenting to the ED in SCD-VOE requiring hospitalization for pain.

Methods: This prospective observational cohort study was a planned sub-analysis of the multicenter phase-3 randomized controlled trial evaluating the efficacy and safety of intravenous arginine for SCD-VOE. This study was conducted at 10 US sites coordinated by the Pediatric Emergency Care Applied Research Network from 2022-2024. Data on type and volume of FB were collected. Patients were divided into 2 groups; those who received a NSB in the ED and those who did not. Patients receiving a Lactated Ringers (LR) bolus were excluded from analyses. Pain was rated using the Verbal Numeric Rating Scale (0-10, no pain to worst pain) and the Stoplight Pain Scale (SPS), a 3-faces pain assessment tool which categorizes pain as “green” (I’m ok; I feel fine right now), “yellow” (I’m not sure, Ask me again later), and “red” (I hurt, I need something to feel better). The association of NSB use on ED/hospital length of stay (LOS), morphine administration, change in pain scores and ACS were evaluated. Descriptive statistics and correlations were calculated overall and by NSB use via Fisher’s exact test for categorical variables with Wilcoxon rank-sum test for continuous variables. A linear regression model predicting change in pain score from presentation to ED disposition was used to determine if NSB was associated with change in pain when controlling for other demographic and clinical factors.

Results: 271 participants were enrolled; 77 (28.4%) received a FB; 72/77 (94%) received NSB and 5/77 (6%) received LR, with median bolus of 20 ml/kg  [IQR 14.0, 20.0] and substantial practice variation in NSB use amongst the 10 centers from 0%-43% of enrolled patients. Of patients who received NSB, 38 (52.8%) were male, 51 (70.8%) had HB-SS genotype with no differences between groups. Patients who received a NSB were younger with a median age of 13.0 years [IQR 10.5, 15.6] compared with 15.5 years [IQR 11.9, 18.2]. An additional 7 patient received a NSB after admission. Highest ED pain scores were similar between groups. There was no significant difference in change in pain scores on day 1 or day 2, or from arrival-to-ED-disposition. Although it did not reach statistical significance, children in the NSB group had a higher proportion of worst pain, “red,” within 12 hours of enrollment and over the next 3 days (18.1%, n=13) vs  (12.9%, n=25). Those with NSB had a shorter median ED length of stay (LOS) of 6.6 [IQR 5.0, 8.2] vs. 7.2 [IQR 5.3, 10.6] hours, p=0.02; while total LOS showed no significant difference. Children that received a NSB had a higher incidence of ACS at presentation compared to children with no NSB (13.9%, n=10) vs. (4.6%, n=9; p=0.015). However, there was no difference in those that developed ACS during the hospital stay in the NSB group (15.2%, n=12) vs. (11.9%, n=22).

Conclusion: Fluid management in pediatric SCD-VOE remains variable. While routine use of NSB has decreased significantly over the last decade, in this prospective observational trial of children and young adults with SCD-VOE requiring hospitalization for pain, nearly one-third received NSB administration. It is likely that a subgroup had a clinical indication that warranted a FB. NSB may impact pain outcomes and this requires further investigation. Whether LR is a better choice for patients requiring a FB remains to be determined.

Claudia Morris, MD: TRILITY - Consultancy (Includes expert testimony); CSL Behring, F. Hoffmann-La Roche LTD - Consultancy (Includes expert testimony); octapharma - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)